Bloating Labs and Next Steps: The Complete Diagnostic Workup

Why Bloating Happens: Physiology and Common Triggers

Bloating arises from a mismatch between gas production, gas transit, and visceral sensitivity in the gut. The sensation itself involves two distinct components: objective abdominal distension (measurable girth increase) and subjective bloating (the feeling of pressure or fullness without visible swelling). Both can occur independently.

Gas accumulates through three main routes. Aerophagia (swallowed air) accounts for most stomach gas. Bacterial fermentation of undigested carbohydrates in the colon produces hydrogen, methane, and carbon dioxide. A third, often overlooked source is impaired gas clearance, where normal volumes of gas cause symptoms because transit through the intestine slows or the diaphragm and abdominal wall muscles respond abnormally 1.

A 2013 review in the Journal of Neurogastroenterology and Motility documented that patients with functional bloating do not always produce more gas than controls. Instead, they exhibit altered abdominal accommodation reflexes, meaning the diaphragm descends and the anterior abdominal wall relaxes inappropriately, creating visible distension even with normal gas volumes 1. Visceral hypersensitivity, a hallmark of irritable bowel syndrome (IBS), amplifies the perception of even small amounts of luminal distension 2.

Common triggers include high-FODMAP foods (onions, garlic, wheat, certain fruits), carbonated drinks, rapid eating, and sugar alcohols found in sugar-free products. Hormonal fluctuations during the luteal phase of the menstrual cycle also increase bloating reports in premenopausal women. Medications, including metformin, acarbose, and GLP-1 receptor agonists, can slow gastric emptying and contribute to upper abdominal bloating in the first weeks of therapy.

The question is not whether bloating has a cause. It always does. The question is whether that cause is functional or structural, and labs are where the answer starts.

Red Flags That Require Prompt Medical Evaluation

Most bloating is benign. Some is not. Distinguishing the two depends on recognizing alarm features that shift the pretest probability toward organic disease.

The Rome IV criteria, published in Gastroenterology in 2016, define functional abdominal bloating as recurrent bloating or distension occurring at least one day per week for three months with onset at least six months prior, in the absence of alarm features 2. Those alarm features include unintentional weight loss exceeding 5 percent of body weight over six months, new-onset bloating after age 50 without prior GI symptoms, rectal bleeding or melena, progressive dysphagia, persistent vomiting, palpable abdominal or pelvic mass, and a family history of ovarian, gastric, or colorectal cancer.

The American College of Obstetricians and Gynecologists (ACOG) specifically warns that persistent bloating lasting more than two to three weeks in women warrants evaluation for ovarian pathology, because ovarian cancer presents with vague abdominal symptoms in over 70 percent of cases 3.

Do not wait. If any alarm feature is present, your physician should skip the trial-of-dietary-change step and proceed directly to bloodwork, imaging, or referral.

The Initial Lab Panel Your Doctor Should Order

A structured first-line lab panel can rule out or identify the most common organic causes of chronic bloating within a single blood draw. There is no universally mandated "bloating panel," but gastroenterology practice guidelines and expert consensus converge on several key tests.

Complete blood count (CBC). Anemia, particularly iron-deficiency anemia with low MCV, raises suspicion for celiac disease, colorectal malignancy, or chronic GI blood loss. Elevated white blood cell count suggests infection or inflammation.

Comprehensive metabolic panel (CMP). Albumin and total protein levels help screen for malabsorption. Elevated liver enzymes may point toward hepatic congestion or biliary pathology contributing to upper abdominal fullness. Glucose levels flag undiagnosed diabetes, which can cause gastroparesis and secondary bloating.

Thyroid-stimulating hormone (TSH). Hypothyroidism slows colonic transit time and is present in up to 5 percent of the general adult population, many of whom are undiagnosed 4. A single TSH measurement is inexpensive and can identify a correctable cause.

Tissue transglutaminase IgA (tTG-IgA) with total serum IgA. This is the preferred serologic screening test for celiac disease per the 2013 ACG Clinical Guidelines, which state: "All patients with symptoms, signs, or laboratory evidence of malabsorption should be tested for celiac disease" 5. Total serum IgA is checked simultaneously because 2 to 3 percent of celiac patients are IgA-deficient, which would produce a false-negative tTG-IgA result. In those cases, IgG-based testing (deamidated gliadin peptide IgG) is substituted.

Celiac disease affects approximately 1 percent of the global population, but the average diagnostic delay exceeds 10 years in adults 5. Bloating is one of its most common presenting complaints.

C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). These markers help distinguish inflammatory bowel disease (IBD) from functional disorders. A 2015 meta-analysis in the American Journal of Gastroenterology found that combining negative CRP with negative fecal calprotectin yields a negative predictive value above 97 percent for excluding IBD in patients presenting with IBS-type symptoms 6.

If every test in this panel returns normal, the probability of an organic cause drops substantially, and the clinical focus shifts to functional bloating, SIBO testing, or dietary evaluation.

Breath Testing and Stool Markers

When first-line blood tests are unrevealing, the next diagnostic layer targets the gut lumen itself: what bacteria are producing, what the intestine is (or isn't) absorbing, and whether mucosal inflammation is present.

Hydrogen-methane breath testing. This is the primary non-invasive method for diagnosing small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption. The patient ingests a substrate (glucose or lactulose) after an overnight fast, and exhaled hydrogen and methane concentrations are measured at 15- to 20-minute intervals over 90 to 120 minutes. The 2020 ACG Clinical Guideline on SIBO recommends glucose breath testing as the preferred substrate for SIBO diagnosis, noting that "a rise in hydrogen of 20 ppm or greater from baseline within 90 minutes of glucose ingestion is considered a positive test" 7. Elevated methane (now classified as intestinal methanogen overgrowth, or IMO) is specifically linked to constipation-predominant symptoms and bloating.

Lactulose breath testing has higher sensitivity but lower specificity than glucose and is used when clinical suspicion remains high despite a negative glucose test 8.

Separate breath tests using lactose or fructose as substrates can diagnose specific carbohydrate malabsorption syndromes, which respond well to targeted dietary exclusion.

Fecal calprotectin. This stool marker detects neutrophilic inflammation in the intestinal wall. A systematic review published in the BMJ analyzed 13 studies with 1,466 patients and found that fecal calprotectin had a pooled sensitivity of 93 percent and specificity of 96 percent for distinguishing IBD from IBS in adults 9. A level below 50 mcg/g makes IBD very unlikely. Levels above 250 mcg/g strongly suggest active mucosal inflammation and warrant endoscopic evaluation.

Fecal elastase-1. This test screens for exocrine pancreatic insufficiency (EPI), which causes maldigestion of fats and proteins, producing bloating, steatorrhea, and weight loss. Levels below 200 mcg/g suggest moderate insufficiency; below 100 mcg/g indicates severe EPI 10.

These tests fill the gap that bloodwork cannot reach. A normal CBC and CMP paired with a positive glucose breath test, for example, changes the entire treatment plan.

When Imaging or Endoscopy Is Needed

Not every patient with bloating needs a CT scan or a scope. Imaging and invasive procedures are reserved for cases where alarm features are present, lab results are abnormal, or symptoms persist despite targeted empiric treatment.

Abdominal ultrasound. This is typically the first imaging study ordered. It is non-invasive, radiation-free, and effective at detecting gallstones, liver pathology, ascites, ovarian masses, and large abdominal lymphadenopathy. For women with persistent bloating and pelvic symptoms, transvaginal ultrasound combined with CA-125 measurement may be appropriate, though CA-125 alone is not reliable for screening 3.

CT abdomen and pelvis. Indicated when alarm features are present, ultrasound is inconclusive, or the clinical picture suggests mesenteric pathology, obstruction, or malignancy. CT enterography with oral contrast specifically evaluates small bowel Crohn's disease and can identify strictures that trap gas and cause episodic distension.

Upper endoscopy (EGD). Ordered when celiac serology is positive (to obtain duodenal biopsies for histologic confirmation per ACG guidelines) or when dyspepsia, dysphagia, or weight loss accompanies bloating 5. Small bowel aspirate obtained during EGD remains the reference standard for SIBO diagnosis, with a colony count exceeding 10^3 CFU/mL now accepted as the diagnostic threshold 7.

Colonoscopy. The ACG recommends colonoscopy for patients with bloating and alarm features such as rectal bleeding, iron-deficiency anemia, new onset of symptoms after age 45, or a family history of colorectal cancer 11. Routine colonoscopy for bloating alone, in the absence of alarm features, has a low diagnostic yield.

The decision tree is straightforward. Normal labs and no alarm features mean imaging can often be deferred. Abnormal labs or red flags mean imaging should not wait.

Matching a Diagnosis to Targeted Treatment

The value of a structured workup is that treatment becomes specific rather than generic. Each diagnosis identified through the lab-to-imaging pipeline has its own evidence-based intervention.

Celiac disease requires strict lifelong gluten exclusion. No partial measures work. Mucosal healing on repeat biopsy is the gold standard for confirming dietary adherence, and most patients see bloating resolve within 2 to 12 weeks of complete gluten removal 5.

SIBO is treated with antibiotics. Rifaximin 550 mg three times daily for 14 days is the most studied regimen. The TARGET 3 trial (N=636) demonstrated that rifaximin produced significant improvement in bloating and global IBS symptoms compared to placebo, with a number needed to treat of 10.2 12. For methane-dominant SIBO (IMO), combination therapy with rifaximin plus neomycin or rifaximin plus metronidazole shows higher methane eradication rates than rifaximin alone.

Exocrine pancreatic insufficiency responds to pancreatic enzyme replacement therapy (PERT) taken with meals. Dosing starts at 40,000 to 50,000 lipase units per meal and is titrated based on symptom response and fecal fat normalization 10.

Hypothyroidism-related bloating resolves with levothyroxine replacement titrated to normalize TSH, typically within 6 to 8 weeks of reaching a therapeutic dose 4.

Functional bloating (Rome IV) without an identified organic cause is managed with a stepwise approach. Dr. Brian Lacy, a gastroenterologist at the Mayo Clinic and lead author of the Rome IV bowel disorders chapter, has noted that "the management of functional bloating requires a multifaceted approach addressing diet, gut microbiota, visceral hypersensitivity, and psychosocial factors" 2. First-line options include a low-FODMAP diet, peppermint oil capsules (which relax intestinal smooth muscle), and probiotics containing Bifidobacterium infantis 35624 or Lactobacillus plantarum 299v, both of which have shown modest benefit in randomized trials.

Medication-induced bloating, particularly from metformin or GLP-1 receptor agonists, typically improves with slower dose titration or switching to extended-release formulations.

Dietary Interventions With Clinical Support

Diet modification is the most accessible intervention for bloating, but "eat better" is not a treatment plan. Specific dietary protocols have been tested in controlled trials, and the data favor structured approaches over vague advice.

The low-FODMAP diet, developed at Monash University, restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols for 4 to 6 weeks, followed by systematic reintroduction. A 2014 randomized controlled trial published in Gastroenterology (N=30 crossover design) found that a low-FODMAP diet reduced overall GI symptoms by 50 percent compared to a typical Australian diet, with bloating specifically showing significant improvement 13. Approximately 70 percent of IBS patients respond to this approach.

This diet should be supervised by a registered dietitian. The elimination phase is intentionally temporary. Long-term full FODMAP restriction can reduce beneficial Bifidobacteria populations in the colon and limit dietary variety unnecessarily.

Other targeted strategies include spacing meals 4 to 5 hours apart to allow the migrating motor complex (the gut's "housekeeper wave") to clear residual food and bacteria between meals, limiting sugar alcohols (sorbitol, mannitol, xylitol) found in diet products, reducing carbonated beverages, and eating slowly to minimize aerophagia.

Fiber supplementation has a nuanced evidence base. Soluble fiber (psyllium) at doses of 5 to 10 g per day improves overall IBS symptoms, including bloating, in several meta-analyses 14. Insoluble fiber (wheat bran) can worsen bloating and should be avoided in patients with gas-predominant symptoms.

For patients whose bloating persists after dietary optimization and negative testing, gut-directed hypnotherapy has Level 1 evidence from multiple RCTs showing sustained symptom improvement lasting 5 years or more after a standard 7- to 12-session protocol.

Fecal calprotectin below 50 mcg/g, a normal CBC, and a negative tTG-IgA collectively reduce the probability of organic bowel disease to under 3 percent in patients meeting Rome IV criteria for functional bloating 6. Start with the labs. Match the result to the treatment. Skip the guesswork.